Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference

2018 ◽  
Vol 101 (2) ◽  
pp. 274-284 ◽  
Author(s):  
William A. Hall ◽  
Carmen Bergom ◽  
Reid F. Thompson ◽  
Andrew M. Baschnagel ◽  
Srinivasan Vijayakumar ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Precision Medicine ◽  
National Cancer Institute ◽  
Radiation Oncology ◽  
American Association ◽  
Precision Oncology ◽  
American Society

Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies

2020 ◽  
Vol 10 (5) ◽  
pp. 324-329 ◽  
Author(s):  
Vivek Verma ◽  
Ethan B. Ludmir ◽  
Shane M. Mesko ◽  
Eric D. Brooks ◽  
Alexander Augustyn ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Radiation Oncology ◽  
Insurance Coverage ◽  
Commercial Insurance ◽  
American Society

scholarly journals Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline

2018 ◽  
Vol 8 (3) ◽  
pp. 145-152 ◽  
Author(s):  
Benjamin D. Smith ◽  
Jennifer R. Bellon ◽  
Rachel Blitzblau ◽  
Gary Freedman ◽  
Bruce Haffty ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Radiation Oncology ◽  
Evidence Based ◽  
Executive Summary ◽  
American Society ◽  
Evidence Based Guideline

scholarly journals Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine

2021 ◽  
Vol 11 ◽  
Author(s):  
Sophia C. Kamran ◽  
Jason A. Efstathiou
Keyword(s):  
Radiation Therapy ◽  
Precision Medicine ◽  
Tumor Biology ◽  
Precision Oncology ◽  
Cancer Management ◽  
Genitourinary Cancer ◽  
Current State ◽  
Molecular Therapies ◽  
Targeted Molecular Therapies ◽  
Development And Validation

Radiation therapy plays a crucial role for the management of genitourinary malignancies, with technological advancements that have led to improvements in outcomes and decrease in treatment toxicities. However, better risk-stratification and identification of patients for appropriate treatments is necessary. Recent advancements in imaging and novel genomic techniques can provide additional individualized tumor and patient information to further inform and guide treatment decisions for genitourinary cancer patients. In addition, the development and use of targeted molecular therapies based on tumor biology can result in individualized treatment recommendations. In this review, we discuss the advances in precision oncology techniques along with current applications for personalized genitourinary cancer management. We also highlight the opportunities and challenges when applying precision medicine principles to the field of radiation oncology. The identification, development and validation of biomarkers has the potential to personalize radiation therapy for genitourinary malignancies so that we may improve treatment outcomes, decrease radiation-specific toxicities, and lead to better long-term quality of life for GU cancer survivors.

scholarly journals Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

2020 ◽  
Vol 38 (18) ◽  
pp. 2080-2106 ◽  
Author(s):  
Nadine M. Tung ◽  
Judy C. Boughey ◽  
Lori J. Pierce ◽  
Mark E. Robson ◽  
Isabelle Bedrosian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Radiation Therapy ◽  
Clinical Oncology ◽  
Radiation Oncology ◽  
Single Agent ◽  
Significant Risk ◽  
Surgical Oncology ◽  
Bilateral Mastectomy ◽  
Eligibility Criteria ◽  
American Society

PURPOSE To develop recommendations for management of patients with breast cancer (BC) with germline mutations in BC susceptibility genes. METHODS The American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology convened an Expert Panel to develop recommendations based on a systematic review of the literature and a formal consensus process. RESULTS Fifty-eight articles met eligibility criteria and formed the evidentiary basis for the local therapy recommendations; six randomized controlled trials of systemic therapy met eligibility criteria. RECOMMENDATIONS Patients with newly diagnosed BC and BRCA1/ 2 mutations may be considered for breast-conserving therapy (BCT), with local control of the index cancer similar to that of noncarriers. The significant risk of a contralateral BC (CBC), especially in young women, and the higher risk of new cancers in the ipsilateral breast warrant discussion of bilateral mastectomy. Patients with mutations in moderate-risk genes should be offered BCT. For women with mutations in BRCA1/ 2 or moderate-penetrance genes who are eligible for mastectomy, nipple-sparing mastectomy is a reasonable approach. There is no evidence of increased toxicity or CBC events from radiation exposure in BRCA1/ 2 carriers. Radiation therapy should not be withheld in ATM carriers. For patients with germline TP53 mutations, mastectomy is advised; radiation therapy is contraindicated except in those with significant risk of locoregional recurrence. Platinum agents are recommended versus taxanes to treat advanced BC in BRCA carriers. In the adjuvant/neoadjuvant setting, data do not support the routine addition of platinum to anthracycline- and taxane-based chemotherapy. Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and talazoparib) are preferable to nonplatinum single-agent chemotherapy for treatment of advanced BC in BRCA1/ 2 carriers. Data are insufficient to recommend PARP inhibitor use in the early setting or in moderate-penetrance carriers. Additional information available at www.asco.org/breast-cancer-guidelines .

Sign in / Sign up

Export Citation Format

Share Document